Leerink Partners analyst Mani Foroohar maintained a Buy rating on CureVac (CVAC – Research Report) on April 16. The company’s shares closed yesterday at $2.57.
According to TipRanks, Foroohar is an analyst with an average return of -6.8% and a 39.31% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, RegenXBio, and BridgeBio Pharma.
CureVac has an analyst consensus of Moderate Buy.
The company has a one-year high of $12.36 and a one-year low of $2.54. Currently, CureVac has an average volume of 773.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CureVac (CVAC) Company Description:
CureVac BV a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company’s product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.
